Luke Walker
Chief Tech/Sci/R&D Officer bij HARPOON THERAPEUTICS, INC.
Profiel
Luke N.
Walker is currently the Chief Medical Officer at Harpoon Therapeutics, Inc. Prior to this, he held the position of Vice President-Clinical Development at Seagen Inc. and Cascadian Therapeutics LLC.
He received his undergraduate and graduate degrees from the University of Oklahoma.
Actieve functies van Luke Walker
| Bedrijven | Functie | Begin |
|---|---|---|
| HARPOON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 03-10-2022 |
Eerdere bekende functies van Luke Walker
| Bedrijven | Functie | Einde |
|---|---|---|
| CASCADIAN THERAPEUTICS INC (USA) | Chief Tech/Sci/R&D Officer | 09-03-2018 |
| SEAGEN INC. | Corporate Officer/Principal | - |
Opleiding van Luke Walker
| University of Oklahoma | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| HARPOON THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
